Clinical trial · Observational
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer
NCT06145139CI-TRIAL-00071593KIDNEY-PAGERenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cancer | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- ctDNA can identify high risk patients
- timeFrame
- baseline, 1 year, 2 year and 3 year
- description
- ctDNA will be determined and levels will be measured, and correlated to relapse status, progression free survival, treatment response and overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with a locoregional cancer in the kidney, and with a tumour available for surgical excision, and sufficient performance status for surgery. * Patients with M1 disease, but no evidence of disease after surgery and local treatment of the metastases. * Core needle biopsy-proven renal cell carcinoma - all histologic subtypes acceptable, clinical tumour stage I-IV * Patients 18 years or older * Patients able to understand and sign written informed consent * Scheduled for curative intent resectional surgery (partial or radical nephrectomy) Exclusion Criteria: * Patients with local disease who are not being offered a nephrectomy. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study
References
Publications (0)
Data not yet available
No reference posted for this study.